The longest-running randomised trial of metabolic surgery found 58% of patients achieved remission, compared with 3% receiving intensive medical and lifestyle treatment.
People with type 2 diabetes were far more likely to put the disease into remission after metabolic-bariatric surgery than after intensive medical and lifestyle treatment, according to a long-running study published in Diabetes Care. The research followed participants for a median of 11 years, with some tracked for as long as 14 years, and found that 58% of those assigned to surgery reached remission, compared with just 3% in the non-surgical group.
The trial, known as ARMMS-T2D, is the largest and longest-running randomised study of metabolic surgery for diabetes. It analysed 262 adults with type 2 diabetes, including 166 assigned to surgery and 96 to medical and lifestyle management. Remission was defined as an HbA1c reading below 6.5% without glucose-lowering medication. HbA1c is a blood test that reflects average blood sugar levels over roughly three months.
Researchers also found that remission was more likely among people who had had diabetes for a shorter time, were not using insulin and were taking fewer blood-sugar-lowering drugs before treatment. Greater weight loss in the first year after treatment was also linked with a better chance of remission. On the other hand, relapse after an initial remission was more common in people with a longer history of diabetes and those already using more classes of medication, suggesting that a patient’s pre-treatment history remains a strong clue to long-term outcome.
The findings add to a growing body of evidence that metabolic surgery can deliver durable benefits for selected patients with diabetes. A separate 2026 study published in Clinical Nutrition found that 53.3% of patients who underwent Roux-en-Y gastric bypass maintained remission after 10 years, while a 2025 study in Surgical Endoscopy reported that 38% of patients remained in remission 15 years after the procedure. Those studies also pointed to insulin dependence, diabetes duration and early postoperative weight loss as important predictors, reinforcing the idea that timing and patient selection matter as much as the operation itself.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
